Patients with multiple sclerosis treated with natalizumab may rarely develop progressive multifocal leukoencephalopathy (PML), a serious and often fatal disease caused by infection with JC virus. The ...

Patients with multiple sclerosis (MS) should be evaluated before, and regularly during, treatment with fingolimod (Gilenya, Novartis) to identify signs and symptoms possibly linked to progressive ...

Progressive Multifocal Leukoencephalopathy (PML): Although no cases of PML have occurred in BRIUMVI-treated MS patients, JCV infection resulting in PML has been observed in patients treated with other ...

Multiple sclerosis patients using Biogen Idec (NASDAQ:BIIB) drug Tysabri now have access to the first test that can help determine their risk for developing a rare but potentially fatal brain ...

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed its review of Tysabri, the Biogen multiple sclerosis drug associated with increased risk of developing ...

Poster Presentation Title: No Association between Decreases in Serum Immunoglobulin Levels and Serious Infections with Long-Term Ublituximab Treatment in Patients with Relapsing Multiple Sclerosis ...

Tyruko ® (natalizumab-sztn), a biosimilar to Tysabri ® (natalizumab), has been made available by Sandoz, according to developer Polpharma Biologics. Tyruko is an integrin receptor antagonist approved ...

There is currently no cure for Multiple Sclerosis (MS). Patients rarely do well with no therapy at all, and it is generally recommended that patients with a confident diagnosis of MS begin treatment ...